Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Interactive algorithm tool with NCCN Guidelines^® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 16, 2021